OBJECTIVES: The biomarkers of an immunological dysregulation due to a chronic Hepatitis B virus (HBV) infection are indeed understudied. If untreated, this condition may evolve into liver impairment also co-occurred by extrahepatic involvements. Here, we aim to identify a new panel of biomarkers including IgG subclasses, Rheumatoid Factor (RF), and Free Light Chains (FLC) that may result useful and reliable for clinical evaluation of HBV-related cryoglobulinemia.METHODS: We retrospectively analyzed clinical data from 44 HBV positive patients. Patients were stratified on the presence/absence of mixed cryoglobulinemia in two group: 22 with cryoglobulins (CGs) and 22 without CGs. Samples from 20 healthy blood donors (HD) were used as negative controls. Serum samples were tested for IgG subclasses, RF (IgM, IgG, and IgA type), and FLC.RESULTS: We detected a strikingly different serum IgG subclasses distribution between HD and HBV positive patients together with different RF isotypes; FLC were significantly increased in HBV-patients if compared with HD while no significant difference was shown between HBV with/without MC.CONCLUSION: The immune-inflammatory response triggered by HBV may be monitored by a peculiar profile of biomarkers. Our results open new perspective in precision medicine era; in these challenging times, they could be also employed to monitor the clinical course of COVID-19 patients, at high risk of HBV reactivation due to liver impairment and/or immunosuppressive therapies.

Pocino, K., Napodano, C., Gragnani, L., Ciasca, G., Colantuono, S., Marri, S., Vantaggio, L., Gulli, F., Lorini, S., Barini, A., Stefanile, A., Miele, L., Casato, M., Zignego, A. L., Rapaccini, G. L., Marino, M., Visentini, M., Basile, U., Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression, <<RHEUMATOLOGY>>, 2021; (Feb 16): 1-10. [doi:10.1093/rheumatology/keab157] [http://hdl.handle.net/10807/177871]

Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression

Pocino, Krizia
Co-primo
;
Napodano, Cecilia
Co-primo
;
Ciasca, Gabriele;Stefanile, Annunziata;Miele, Luca;Rapaccini, Gian Ludovico;Marino, Mariapaola
;
Basile, Umberto
Ultimo
2021

Abstract

OBJECTIVES: The biomarkers of an immunological dysregulation due to a chronic Hepatitis B virus (HBV) infection are indeed understudied. If untreated, this condition may evolve into liver impairment also co-occurred by extrahepatic involvements. Here, we aim to identify a new panel of biomarkers including IgG subclasses, Rheumatoid Factor (RF), and Free Light Chains (FLC) that may result useful and reliable for clinical evaluation of HBV-related cryoglobulinemia.METHODS: We retrospectively analyzed clinical data from 44 HBV positive patients. Patients were stratified on the presence/absence of mixed cryoglobulinemia in two group: 22 with cryoglobulins (CGs) and 22 without CGs. Samples from 20 healthy blood donors (HD) were used as negative controls. Serum samples were tested for IgG subclasses, RF (IgM, IgG, and IgA type), and FLC.RESULTS: We detected a strikingly different serum IgG subclasses distribution between HD and HBV positive patients together with different RF isotypes; FLC were significantly increased in HBV-patients if compared with HD while no significant difference was shown between HBV with/without MC.CONCLUSION: The immune-inflammatory response triggered by HBV may be monitored by a peculiar profile of biomarkers. Our results open new perspective in precision medicine era; in these challenging times, they could be also employed to monitor the clinical course of COVID-19 patients, at high risk of HBV reactivation due to liver impairment and/or immunosuppressive therapies.
Inglese
Pocino, K., Napodano, C., Gragnani, L., Ciasca, G., Colantuono, S., Marri, S., Vantaggio, L., Gulli, F., Lorini, S., Barini, A., Stefanile, A., Miele, L., Casato, M., Zignego, A. L., Rapaccini, G. L., Marino, M., Visentini, M., Basile, U., Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression, <<RHEUMATOLOGY>>, 2021; (Feb 16): 1-10. [doi:10.1093/rheumatology/keab157] [http://hdl.handle.net/10807/177871]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/177871
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact